Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 41,139,870 | 38,903,720 | 37,797,960 | 36,578,270 | 37,916,180 |
| Cost of Goods | 13,669,690 | 13,328,770 | 12,590,740 | 13,536,240 | 12,069,030 |
| Gross Profit | 27,470,180 | 25,574,950 | 25,207,220 | 23,042,030 | 25,847,150 |
| Operating Expenses | 20,152,160 | 20,308,390 | 21,686,890 | 7,259,930 | 20,429,870 |
| Operating Income | 7,318,708 | 5,267,326 | 3,521,069 | 15,782,340 | 5,417,309 |
| Interest Expense | 1,065,170 | 945,979 | 997,501 | 1,157,453 | 1,198,160 |
| Other Income | 153,502 | 221,673 | 104,359 | 1,469,363 | 672,411 |
| Pre-tax Income | 6,407,040 | 4,543,020 | 2,627,927 | 16,094,250 | 4,891,560 |
| Income Tax | 1,006,439 | 1,747,613 | 1,188,598 | 3,293,466 | 225,780 |
| Net Income Continuous | 5,400,601 | 2,795,407 | 1,439,329 | 12,800,790 | 6,905,888 |
| Minority Interests | 564,620 | 820,966 | 203,295 | -76,450 | N/A |
| Net Income | $4,835,980 | $1,974,442 | $1,236,034 | $12,877,240 | $4,665,770 |
| EPS Basic Total Ops | 2.46 | 1.01 | 0.64 | 6.66 | 2.16 |
| EPS Basic Continuous Ops | 2.75 | 1.43 | 0.74 | 6.62 | 3.59 |
| EPS Diluted Total Ops | 2.43 | 1.00 | 0.63 | 6.59 | 2.14 |
| EPS Diluted Continuous Ops | 2.72 | 1.41 | 0.73 | 6.55 | 3.55 |
| EPS Diluted Before Non-Recurring Items | 3.95 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $9,796,096 | $7,744,402 | $5,925,369 | $18,274,610 | $8,756,358 |